Sökning: "breast cancer resistance protein"
Visar resultat 11 - 15 av 67 avhandlingar innehållade orden breast cancer resistance protein.
11. The receptor tyrosine kinase Met and the protein tyrosine phosphatase PTPN2 in breast cancer
Sammanfattning : Breast cancer is the most common form of cancer in women worldwide and the second leading cause of cancer death. It is a heterogeneous disease and is subdivided into different subtypes, all with different treatment responses and survival outcomes. LÄS MER
12. Body constitution, statin use, and tumor characteristics. Implications for prognosis
Sammanfattning : Breast cancer is an important cause of disease-burden and death in women. To prevent over- and undertreatment of breast cancer patients, new prognostic and predictive factors are needed. LÄS MER
13. Protein Kinase C as an Apoptosis Regulator and a Potential Prognostic Factor in Breast Cancer
Sammanfattning : Several protein kinase C (PKC) isoforms have been suggested as potential targets for breast cancer therapy. To explore the role for PKC isoforms in processes that facilitates malignant progression and the utility of PKC isoforms as biomarkers in breast cancer, we designed a study where we evaluated the expression of PKCα, δ, and ε in primary breast cancers as well as in breast cancer cell lines. LÄS MER
14. Transcriptional Regulation by Hypoxia-Inducible Factors in Tumor Cells
Sammanfattning : Cancer is a major cause of human morbidity and mortality, and the risk of developing cancer is about one in three life times. Neuroblastoma is the most common extra-cranial solid tumor among children and arises from early sympathetic nervous system (SNS) cells arrested in their development. LÄS MER
15. MicroRNAs in HER2-Amplified Breast Cancer
Sammanfattning : Background: Breast cancer is the most common female malignancy and the leading cause of cancer-related deaths worldwide. Targeted therapy against the main biomarkers estrogen receptor alpha (ER) and human epidermal growth factor receptor 2 (HER2/ERBB2) have greatly improved mortality rates, but ab initio or acquired therapy resistance is common. LÄS MER